Global Microbiome Drugs Market Research Report 2022

Lowest Price Available	Length	Published Date	Report Id
from $2,900.00	104 Pages	2022-05-30	4643802

Summary:

Microbiome Drug is a kind of medicine made with microorganisms. According to the source, it is divided into three categories: drugs derived from whole or part of microorganisms, drugs derived from microbial primary metabolites, and drugs derived from microbial secondary metabolites.

Industry Insights

The global Microbiome Drugs market size is projected to reach US$ 1815.7 million by 2028, from US$ 222 million in 2021, at a CAGR of 34.6% during 2022-2028.

North America and Europe hold most of market share of microbiome drugs, and North America occupies a share over 77%, on the other hand, Europe takes a share of over 22% in total. Global core microbiome drugs manufacturers include Seres Therapeutics, Assembly Biosciences, Synthetic Biologics etc.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Microbiome Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Microbiome Drugs market in terms of revenue.

Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Microbiome Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Microbiome Drugs market.

Impact of Covid-19 Outbreak

This section of the report has explored the overall status of the Covid scenario and has offered valuable insights into the changes in supply chain disruption, fluctuations in demand, etc. The analysts have also focused on the key measures that the companies are opting to withstand the harsh scenario.

Segmental Analysis

The report has been segmented into product and application segments. The researchers have documented all the products present today in the Microbiome Drugs market. They have also shed light on the new product innovations and launches by the key players. In the segmental analysis, the analysts have provided revenue forecast figures based on type and application for the period 2017-2028. They have also discussed about the growth rate and potential of each segment for the period 2017-2028.

Microbiome Drugs Breakdown Data by Type

Oral Dosage Form

Enteric Capsules

Microbiome Drugs Breakdown Data by Symptom

Gastrointestinal Disorders

Autoimmune Disorders

Diabetes

Cancer

Others

Regional Analysis

North America

United States

Canada

Europe

Germany

France

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Competitive Landscape

This segment focuses on the key players operating in the industry. It underlines all the current and future activities by the prominent manufacturers. By understanding various initiatives being taken up by different players, readers will gain the ability to settle on correct business choices. The authors of the report have provided accurate revenue figures of the companies for the period 2017-2022. The clients are sure to gain the upper hand once they get hold of this report. Key players studied in the research report include:

Seres Therapeutics

Assembly Biosciences

Synthetic Biologics

Interxon

PureTech

Synlogic

Enterome BioScience

4D Pharma

Second Genome

AOBiome

Rebiotix

Metabiomics

Ritter Pharmaceuticals

Symberix

OpenBiome

Azitra

Osel

Frequently Asked Questions

What factors will challenge the Microbiome Drugs market growth?

Which end-use segment will expand at the fastest CAGR in the Microbiome Drugs market?

Which are the emerging players in the Microbiome Drugs market?

How concentrated is the Microbiome Drugs market?

Which factors are positively contributing to the Microbiome Drugs market growth?

Which are the novel product innovations in the Microbiome Drugs market?

Which product segment will emerge as the most lucrative in the Microbiome Drugs market?

Which factors are increasing the competition in the Microbiome Drugs market?

Which are the strategic measures taken by the Microbiome Drugs industry players?

Which region will witness inactive growth during the forecast period?

What key trends are likely to emerge in the Microbiome Drugs market in the coming years?

Table of Contents

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Microbiome Drugs Market Size Growth Rate by Type: 2017 VS 2021 VS 2028

1.2.2 Oral Dosage Form

1.2.3 Enteric Capsules

1.3 Market by Symptom

1.3.1 Global Microbiome Drugs Market Share by Symptom: 2017 VS 2021 VS 2028

1.3.2 Gastrointestinal Disorders

1.3.3 Autoimmune Disorders

1.3.4 Diabetes

1.3.5 Cancer

1.3.6 Others

1.4 Study Objectives

1.5 Years Considered

2 Global Growth Trends

2.1 Global Microbiome Drugs Market Perspective (2017-2028)

2.2 Microbiome Drugs Growth Trends by Region

2.2.1 Microbiome Drugs Market Size by Region: 2017 VS 2021 VS 2028

2.2.2 Microbiome Drugs Historic Market Size by Region (2017-2022)

2.2.3 Microbiome Drugs Forecasted Market Size by Region (2023-2028)

2.3 Microbiome Drugs Market Dynamics

2.3.1 Microbiome Drugs Industry Trends

2.3.2 Microbiome Drugs Market Drivers

2.3.3 Microbiome Drugs Market Challenges

2.3.4 Microbiome Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Microbiome Drugs Players by Revenue

3.1.1 Global Top Microbiome Drugs Players by Revenue (2017-2022)

3.1.2 Global Microbiome Drugs Revenue Market Share by Players (2017-2022)

3.2 Global Microbiome Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Microbiome Drugs Revenue

3.4 Global Microbiome Drugs Market Concentration Ratio

3.4.1 Global Microbiome Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Microbiome Drugs Revenue in 2021

3.5 Microbiome Drugs Key Players Head office and Area Served

3.6 Key Players Microbiome Drugs Product Solution and Service

3.7 Date of Enter into Microbiome Drugs Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Microbiome Drugs Breakdown Data by Type

4.1 Global Microbiome Drugs Historic Market Size by Type (2017-2022)

4.2 Global Microbiome Drugs Forecasted Market Size by Type (2023-2028)

5 Microbiome Drugs Breakdown Data by Symptom

5.1 Global Microbiome Drugs Historic Market Size by Symptom (2017-2022)

5.2 Global Microbiome Drugs Forecasted Market Size by Symptom (2023-2028)

6 North America

6.1 North America Microbiome Drugs Market Size (2017-2028)

6.2 North America Microbiome Drugs Market Size by Country (2017-2022)

6.3 North America Microbiome Drugs Market Size by Country (2023-2028)

6.4 United States

6.5 Canada

7 Europe

7.1 Europe Microbiome Drugs Market Size (2017-2028)

7.2 Europe Microbiome Drugs Market Size by Country (2017-2022)

7.3 Europe Microbiome Drugs Market Size by Country (2023-2028)

7.4 Germany

7.5 France

7.6 U.K.

7.7 Italy

7.8 Russia

7.9 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Microbiome Drugs Market Size (2017-2028)

8.2 Asia-Pacific Microbiome Drugs Market Size by Country (2017-2022)

8.3 Asia-Pacific Microbiome Drugs Market Size by Country (2023-2028)

8.4 China

8.5 Japan

8.6 South Korea

8.7 Southeast Asia

8.8 India

8.9 Australia

9 Latin America

9.1 Latin America Microbiome Drugs Market Size (2017-2028)

9.2 Latin America Microbiome Drugs Market Size by Country (2017-2022)

9.3 Latin America Microbiome Drugs Market Size by Country (2023-2028)

9.4 Mexico

9.5 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Microbiome Drugs Market Size (2017-2028)

10.2 Middle East & Africa Microbiome Drugs Market Size by Country (2017-2022)

10.3 Middle East & Africa Microbiome Drugs Market Size by Country (2023-2028)

10.4 Turkey

10.5 Saudi Arabia

10.6 UAE

11 Key Players Profiles

11.1 Seres Therapeutics

11.1.1 Seres Therapeutics Company Detail

11.1.2 Seres Therapeutics Business Overview

11.1.3 Seres Therapeutics Microbiome Drugs Introduction

11.1.4 Seres Therapeutics Revenue in Microbiome Drugs Business (2017-2022)

11.1.5 Seres Therapeutics Recent Development

11.2 Assembly Biosciences

11.2.1 Assembly Biosciences Company Detail

11.2.2 Assembly Biosciences Business Overview

11.2.3 Assembly Biosciences Microbiome Drugs Introduction

11.2.4 Assembly Biosciences Revenue in Microbiome Drugs Business (2017-2022)

11.2.5 Assembly Biosciences Recent Development

11.3 Synthetic Biologics

11.3.1 Synthetic Biologics Company Detail

11.3.2 Synthetic Biologics Business Overview

11.3.3 Synthetic Biologics Microbiome Drugs Introduction

11.3.4 Synthetic Biologics Revenue in Microbiome Drugs Business (2017-2022)

11.3.5 Synthetic Biologics Recent Development

11.4 Interxon

11.4.1 Interxon Company Detail

11.4.2 Interxon Business Overview

11.4.3 Interxon Microbiome Drugs Introduction

11.4.4 Interxon Revenue in Microbiome Drugs Business (2017-2022)

11.4.5 Interxon Recent Development

11.5 PureTech

11.5.1 PureTech Company Detail

11.5.2 PureTech Business Overview

11.5.3 PureTech Microbiome Drugs Introduction

11.5.4 PureTech Revenue in Microbiome Drugs Business (2017-2022)

11.5.5 PureTech Recent Development

11.6 Synlogic

11.6.1 Synlogic Company Detail

11.6.2 Synlogic Business Overview

11.6.3 Synlogic Microbiome Drugs Introduction

11.6.4 Synlogic Revenue in Microbiome Drugs Business (2017-2022)

11.6.5 Synlogic Recent Development

11.7 Enterome BioScience

11.7.1 Enterome BioScience Company Detail

11.7.2 Enterome BioScience Business Overview

11.7.3 Enterome BioScience Microbiome Drugs Introduction

11.7.4 Enterome BioScience Revenue in Microbiome Drugs Business (2017-2022)

11.7.5 Enterome BioScience Recent Development

11.8 4D Pharma

11.8.1 4D Pharma Company Detail

11.8.2 4D Pharma Business Overview

11.8.3 4D Pharma Microbiome Drugs Introduction

11.8.4 4D Pharma Revenue in Microbiome Drugs Business (2017-2022)

11.8.5 4D Pharma Recent Development

11.9 Second Genome

11.9.1 Second Genome Company Detail

11.9.2 Second Genome Business Overview

11.9.3 Second Genome Microbiome Drugs Introduction

11.9.4 Second Genome Revenue in Microbiome Drugs Business (2017-2022)

11.9.5 Second Genome Recent Development

11.10 AOBiome

11.10.1 AOBiome Company Detail

11.10.2 AOBiome Business Overview

11.10.3 AOBiome Microbiome Drugs Introduction

11.10.4 AOBiome Revenue in Microbiome Drugs Business (2017-2022)

11.10.5 AOBiome Recent Development

11.11 Rebiotix

11.11.1 Rebiotix Company Detail

11.11.2 Rebiotix Business Overview

11.11.3 Rebiotix Microbiome Drugs Introduction

11.11.4 Rebiotix Revenue in Microbiome Drugs Business (2017-2022)

11.11.5 Rebiotix Recent Development

11.12 Metabiomics

11.12.1 Metabiomics Company Detail

11.12.2 Metabiomics Business Overview

11.12.3 Metabiomics Microbiome Drugs Introduction

11.12.4 Metabiomics Revenue in Microbiome Drugs Business (2017-2022)

11.12.5 Metabiomics Recent Development

11.13 Ritter Pharmaceuticals

11.13.1 Ritter Pharmaceuticals Company Detail

11.13.2 Ritter Pharmaceuticals Business Overview

11.13.3 Ritter Pharmaceuticals Microbiome Drugs Introduction

11.13.4 Ritter Pharmaceuticals Revenue in Microbiome Drugs Business (2017-2022)

11.13.5 Ritter Pharmaceuticals Recent Development

11.14 Symberix

11.14.1 Symberix Company Detail

11.14.2 Symberix Business Overview

11.14.3 Symberix Microbiome Drugs Introduction

11.14.4 Symberix Revenue in Microbiome Drugs Business (2017-2022)

11.14.5 Symberix Recent Development

11.15 OpenBiome

11.15.1 OpenBiome Company Detail

11.15.2 OpenBiome Business Overview

11.15.3 OpenBiome Microbiome Drugs Introduction

11.15.4 OpenBiome Revenue in Microbiome Drugs Business (2017-2022)

11.15.5 OpenBiome Recent Development

11.16 Azitra

11.16.1 Azitra Company Detail

11.16.2 Azitra Business Overview

11.16.3 Azitra Microbiome Drugs Introduction

11.16.4 Azitra Revenue in Microbiome Drugs Business (2017-2022)

11.16.5 Azitra Recent Development

11.17 Osel

11.17.1 Osel Company Detail

11.17.2 Osel Business Overview

11.17.3 Osel Microbiome Drugs Introduction

11.17.4 Osel Revenue in Microbiome Drugs Business (2017-2022)

11.17.5 Osel Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

Table 1. Global Microbiome Drugs Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028

Table 2. Key Players of Oral Dosage Form

Table 3. Key Players of Enteric Capsules

Table 4. Global Microbiome Drugs Market Size Growth by Symptom (US$ Million): 2017 VS 2021 VS 2028

Table 5. Global Microbiome Drugs Market Size by Region (US$ Million): 2017 VS 2021 VS 2028

Table 6. Global Microbiome Drugs Market Size by Region (2017-2022) & (US$ Million)

Table 7. Global Microbiome Drugs Market Share by Region (2017-2022)

Table 8. Global Microbiome Drugs Forecasted Market Size by Region (2023-2028) & (US$ Million)

Table 9. Global Microbiome Drugs Market Share by Region (2023-2028)

Table 10. Microbiome Drugs Market Trends

Table 11. Microbiome Drugs Market Drivers

Table 12. Microbiome Drugs Market Challenges

Table 13. Microbiome Drugs Market Restraints

Table 14. Global Microbiome Drugs Revenue by Players (2017-2022) & (US$ Million)

Table 15. Global Microbiome Drugs Market Share by Players (2017-2022)

Table 16. Global Top Microbiome Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Microbiome Drugs as of 2021)

Table 17. Ranking of Global Top Microbiome Drugs Companies by Revenue (US$ Million) in 2021

Table 18. Global 5 Largest Players Market Share by Microbiome Drugs Revenue (CR5 and HHI) & (2017-2022)

Table 19. Key Players Headquarters and Area Served

Table 20. Key Players Microbiome Drugs Product Solution and Service

Table 21. Date of Enter into Microbiome Drugs Market

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Microbiome Drugs Market Size by Type (2017-2022) & (US$ Million)

Table 24. Global Microbiome Drugs Revenue Market Share by Type (2017-2022)

Table 25. Global Microbiome Drugs Forecasted Market Size by Type (2023-2028) & (US$ Million)

Table 26. Global Microbiome Drugs Revenue Market Share by Type (2023-2028)

Table 27. Global Microbiome Drugs Market Size by Symptom (2017-2022) & (US$ Million)

Table 28. Global Microbiome Drugs Revenue Market Share by Symptom (2017-2022)

Table 29. Global Microbiome Drugs Forecasted Market Size by Symptom (2023-2028) & (US$ Million)

Table 30. Global Microbiome Drugs Revenue Market Share by Symptom (2023-2028)

Table 31. North America Microbiome Drugs Market Size by Country (2017-2022) & (US$ Million)

Table 32. North America Microbiome Drugs Market Size by Country (2023-2028) & (US$ Million)

Table 33. Europe Microbiome Drugs Market Size by Country (2017-2022) & (US$ Million)

Table 34. Europe Microbiome Drugs Market Size by Country (2023-2028) & (US$ Million)

Table 35. Asia-Pacific Microbiome Drugs Market Size by Region (2017-2022) & (US$ Million)

Table 36. Asia-Pacific Microbiome Drugs Market Size by Region (2023-2028) & (US$ Million)

Table 37. Latin America Microbiome Drugs Market Size by Country (2017-2022) & (US$ Million)

Table 38. Latin America Microbiome Drugs Market Size by Country (2023-2028) & (US$ Million)

Table 39. Middle East & Africa Microbiome Drugs Market Size by Country (2017-2022) & (US$ Million)

Table 40. Middle East & Africa Microbiome Drugs Market Size by Country (2023-2028) & (US$ Million)

Table 41. Seres Therapeutics Company Detail

Table 42. Seres Therapeutics Business Overview

Table 43. Seres Therapeutics Microbiome Drugs Product

Table 44. Seres Therapeutics Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)

Table 45. Seres Therapeutics Recent Development

Table 46. Assembly Biosciences Company Detail

Table 47. Assembly Biosciences Business Overview

Table 48. Assembly Biosciences Microbiome Drugs Product

Table 49. Assembly Biosciences Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)

Table 50. Assembly Biosciences Recent Development

Table 51. Synthetic Biologics Company Detail

Table 52. Synthetic Biologics Business Overview

Table 53. Synthetic Biologics Microbiome Drugs Product

Table 54. Synthetic Biologics Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)

Table 55. Synthetic Biologics Recent Development

Table 56. Interxon Company Detail

Table 57. Interxon Business Overview

Table 58. Interxon Microbiome Drugs Product

Table 59. Interxon Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)

Table 60. Interxon Recent Development

Table 61. PureTech Company Detail

Table 62. PureTech Business Overview

Table 63. PureTech Microbiome Drugs Product

Table 64. PureTech Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)

Table 65. PureTech Recent Development

Table 66. Synlogic Company Detail

Table 67. Synlogic Business Overview

Table 68. Synlogic Microbiome Drugs Product

Table 69. Synlogic Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)

Table 70. Synlogic Recent Development

Table 71. Enterome BioScience Company Detail

Table 72. Enterome BioScience Business Overview

Table 73. Enterome BioScience Microbiome Drugs Product

Table 74. Enterome BioScience Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)

Table 75. Enterome BioScience Recent Development

Table 76. 4D Pharma Company Detail

Table 77. 4D Pharma Business Overview

Table 78. 4D Pharma Microbiome Drugs Product

Table 79. 4D Pharma Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)

Table 80. 4D Pharma Recent Development

Table 81. Second Genome Company Detail

Table 82. Second Genome Business Overview

Table 83. Second Genome Microbiome Drugs Product

Table 84. Second Genome Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)

Table 85. Second Genome Recent Development

Table 86. AOBiome Company Detail

Table 87. AOBiome Business Overview

Table 88. AOBiome Microbiome Drugs Product

Table 89. AOBiome Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)

Table 90. AOBiome Recent Development

Table 91. Rebiotix Company Detail

Table 92. Rebiotix Business Overview

Table 93. Rebiotix Microbiome DrugsProduct

Table 94. Rebiotix Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)

Table 95. Rebiotix Recent Development

Table 96. Metabiomics Company Detail

Table 97. Metabiomics Business Overview

Table 98. Metabiomics Microbiome DrugsProduct

Table 99. Metabiomics Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)

Table 100. Metabiomics Recent Development

Table 101. Ritter Pharmaceuticals Company Detail

Table 102. Ritter Pharmaceuticals Business Overview

Table 103. Ritter Pharmaceuticals Microbiome DrugsProduct

Table 104. Ritter Pharmaceuticals Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)

Table 105. Ritter Pharmaceuticals Recent Development

Table 106. Symberix Company Detail

Table 107. Symberix Business Overview

Table 108. Symberix Microbiome DrugsProduct

Table 109. Symberix Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)

Table 110. Symberix Recent Development

Table 111. OpenBiome Company Detail

Table 112. OpenBiome Business Overview

Table 113. OpenBiome Microbiome DrugsProduct

Table 114. OpenBiome Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)

Table 115. OpenBiome Recent Development

Table 116. Azitra Company Detail

Table 117. Azitra Business Overview

Table 118. Azitra Microbiome DrugsProduct

Table 119. Azitra Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)

Table 120. Azitra Recent Development

Table 121. Osel Company Detail

Table 122. Osel Business Overview

Table 123. Osel Microbiome DrugsProduct

Table 124. Osel Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)

Table 125. Osel Recent Development

Table 126. Research Programs/Design for This Report

Table 127. Key Data Information from Secondary Sources

Table 128. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Microbiome Drugs Market Share by Type: 2021 VS 2028

Figure 2. Oral Dosage Form Features

Figure 3. Enteric Capsules Features

Figure 4. Global Microbiome Drugs Market Share by Symptom in 2021 & 2028

Figure 5. Gastrointestinal Disorders Case Studies

Figure 6. Autoimmune Disorders Case Studies

Figure 7. Diabetes Case Studies

Figure 8. Cancer Case Studies

Figure 9. Others Case Studies

Figure 10. Microbiome Drugs Report Years Considered

Figure 11. Global Microbiome Drugs Market Size (US$ Million), Year-over-Year: 2017-2028

Figure 12. Global Microbiome Drugs Market Size, (US$ Million), 2017 VS 2021 VS 2028

Figure 13. Global Microbiome Drugs Market Share by Region: 2021 VS 2028

Figure 14. Global Microbiome Drugs Market Share by Players in 2021

Figure 15. Global Top Microbiome Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Microbiome Drugs as of 2021)

Figure 16. The Top 10 and 5 Players Market Share by Microbiome Drugs Revenue in 2021

Figure 17. North America Microbiome Drugs Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 18. North America Microbiome Drugs Market Share by Country (2017-2028)

Figure 19. United States Microbiome Drugs Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 20. Canada Microbiome Drugs Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 21. Europe Microbiome Drugs Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 22. Europe Microbiome Drugs Market Share by Country (2017-2028)

Figure 23. Germany Microbiome Drugs Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 24. France Microbiome Drugs Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 25. U.K. Microbiome Drugs Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 26. Italy Microbiome Drugs Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 27. Russia Microbiome Drugs Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 28. Nordic Countries Microbiome Drugs Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 29. Asia-Pacific Microbiome Drugs Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 30. Asia-Pacific Microbiome Drugs Market Share by Region (2017-2028)

Figure 31. China Microbiome Drugs Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 32. Japan Microbiome Drugs Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 33. South Korea Microbiome Drugs Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 34. Southeast Asia Microbiome Drugs Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 35. India Microbiome Drugs Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 36. Australia Microbiome Drugs Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 37. Latin America Microbiome Drugs Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 38. Latin America Microbiome Drugs Market Share by Country (2017-2028)

Figure 39. Mexico Microbiome Drugs Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 40. Brazil Microbiome Drugs Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 41. Middle East & Africa Microbiome Drugs Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 42. Middle East & Africa Microbiome Drugs Market Share by Country (2017-2028)

Figure 43. Turkey Microbiome Drugs Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 44. Saudi Arabia Microbiome Drugs Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 45. Seres Therapeutics Revenue Growth Rate in Microbiome Drugs Business (2017-2022)

Figure 46. Assembly Biosciences Revenue Growth Rate in Microbiome Drugs Business (2017-2022)

Figure 47. Synthetic Biologics Revenue Growth Rate in Microbiome Drugs Business (2017-2022)

Figure 48. Interxon Revenue Growth Rate in Microbiome Drugs Business (2017-2022)

Figure 49. PureTech Revenue Growth Rate in Microbiome Drugs Business (2017-2022)

Figure 50. Synlogic Revenue Growth Rate in Microbiome Drugs Business (2017-2022)

Figure 51. Enterome BioScience Revenue Growth Rate in Microbiome Drugs Business (2017-2022)

Figure 52. 4D Pharma Revenue Growth Rate in Microbiome Drugs Business (2017-2022)

Figure 53. Second Genome Revenue Growth Rate in Microbiome Drugs Business (2017-2022)

Figure 54. AOBiome Revenue Growth Rate in Microbiome Drugs Business (2017-2022)

Figure 55. Rebiotix Revenue Growth Rate in Microbiome Drugs Business (2017-2022)

Figure 56. Metabiomics Revenue Growth Rate in Microbiome Drugs Business (2017-2022)

Figure 57. Ritter Pharmaceuticals Revenue Growth Rate in Microbiome Drugs Business (2017-2022)

Figure 58. Symberix Revenue Growth Rate in Microbiome Drugs Business (2017-2022)

Figure 59. OpenBiome Revenue Growth Rate in Microbiome Drugs Business (2017-2022)

Figure 60. Azitra Revenue Growth Rate in Microbiome Drugs Business (2017-2022)

Figure 61. Osel Revenue Growth Rate in Microbiome Drugs Business (2017-2022)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

Purchase This Market
Research Report

USD 2,900 Single License
USD 5,800 Enterprise License

Request Sample

Request Customization

Global Microbiome Drugs Market Research Report 2022

Global Car Security System Mar

Global Hydraulic Hooklift Hois

Canned Fishery Product Market,

Global Coring Drill Stands Mar

Global Poultry Feed Acidifiers

Purchase This Market
Research Report

MarketReports

MARKET REPORTS

Service

Support

About Us

Global Microbiome Drugs Market Research Report 2022

Global Car Security System Mar

Global Hydraulic Hooklift Hois

Canned Fishery Product Market,

Global Coring Drill Stands Mar

Global Poultry Feed Acidifiers

Purchase This MarketResearch Report

MarketReports

MARKET REPORTS

Service

Support

About Us

Purchase This Market
Research Report